JDRF Australia

While we work towards finding a cure for type 1 diabetes (T1D), we’re actively seeking to improve the lives of those currently living with the condition.   That’s why we invest in research centred on life-changing technology used to manage blood glucose levels. This includes technology to more closely mimic the natural workings of the pancreas, known as hybrid closed-loop systems.   As we continue our tour of the impact that JDRF Australia’s Type 1 Diabetes Clinical Research Network (T1DCRN) has had over the past decade, we’re taking a look at how T1DCRN funding is making blood glucose management safer, easier and more effective every day.  

🤔What do the type 1 diabetes (T1D) community, scientists, and JDRF Australia have in common? We all know that research holds the key to a T1D-free future! That’s why we're asking the Government for $50m for T1D research. It will mean we can continue supporting the best and brightest scientists who want to make a difference for Zeph, Ethan, Giselle, and every Australian with T1D.

👀 Maintaining good vision is important to everyone, but we know this is especially top of mind for people with type 1 diabetes (T1D). This is because eyesight complications, including diabetic retinopathy, are relatively common for people who have lived with T1D for a long time.  But what if we could change all this? Professors Alicia Jenkins and Anthony Keech are leading the charge against diabetic retinopathy (DR), a condition that can lead to reduced vision and even blindness. On top of that, the treatment options are invasive and can be pretty scary. Supported by funding from JDRF Australia’s Type 1 Diabetes Clinical Research Network, they’re working with an exciting medication that could make big changes to DR treatments in the future.     Swipe through to discover what they’re working on.  

Let’s hear it for the researchers who dedicate their careers to finding a cure for type 1 diabetes (T1D) – like Dr Ying Wong! 👏 Ying is an early career researcher who is looking at the genes and pathways that may contribute to T1D progressing. This kind of project could one day help stop T1D from happening in the first place. We’re so thankful for researchers like Ying, who are passionate about making a difference for the T1D community. And as Ying says, we’re hopeful for more research funding from the Government, so that one day we'll achieve our goal of a world without T1D 💙

Looking for an exciting way to make a difference as a team? 🚀 The JDRF JUMP Challenge is back! Rally your colleagues—or dare your boss—to take on a thrilling tandem skydive while supporting the type 1 diabetes (T1D) community. 💙 On Sunday, 16 February, skydive for the 130,000+ Aussies living with T1D. ✨ Register today, fundraise for T1D research, and once you hit your target, get ready for an unforgettable ocean-view jump—complete with a photo and video package to capture the moment! Step outside your comfort zone and make a real impact. Sign up now! 

🧫 In type 1 diabetes (T1D) the immune system mistakenly attacks insulin-producing beta cells of the pancreas, meaning that over time, people with T1D stop making their own insulin.   But what if we could halt the progression of T1D in those newly diagnosed?  This would allow them to keep on producing their own insulin for longer, reducing how much man-made insulin they need to use, and leading to better health in the long term.  As we continue our tour of the impact that JDRF Australia’s Type 1 Diabetes Clinical Research Network (T1DCRN) has had over the past decade, we’re taking a look at how T1DCRN funding led to the world-first discovery that a commonly prescribed drug can supress the progression of T1D in those newly diagnosed.   

Preventing or slowing the development of type 1 diabetes (T1D) would be a dream come true - and the good news is that Professor Ranjeny Thomas is working to make this a reality.    With support from the JDRF Type 1 Diabetes Clinical Research Network (T1DCRN) since the early 2000s, Prof Thomas has been working on an immune therapy that could ‘train’ the immune system to stop attacking the insulin-producing beta cells in the pancreas.    Even more exciting? This therapy has recently launched into clinical trials for the first time.    Prof Thomas says that “Research is so important to get new therapies to patients.” #ResearchHoldsTheKey

🎉 JDRF is excited to announce the launch of its new pilot program, our type 1 diabetes (T1D) transition pack for teens! We know that transitioning from paediatric to adult T1D services can be a nerve-wracking experience for teens. To help educate and empower young people (and their parents and carers), JDRF – with the support of Ypsomed Australia PTY Ltd – has created a program that includes a transition pack and SMS video series for young people. Find out what's in the pack, how it works, and how to find out more ⬇️⬇️⬇️

Are you a researcher in type 1 diabetes (T1D)? Stay updated on T1D research news by subscribing to our Research Insider Newsletter!   Our next edition will be coming out next week and will be jam packed with news about JDRF funding opportunities, research updates, events and clinical trials currently open.   Don’t miss out! 🔬   Subscribe now: https://lnkd.in/gUKs8Atr

Would you like to see a future that includes precision medicine – that is, the right treatment, for the right person, at the right time – for type 1 diabetes (T1D)?   So would Professor Simon Barry, a molecular biologist funded through the JDRF Australia Type 1 Diabetes Clinical Research Network (T1DCRN).   Professor Barry works in genomics research, which we need to move us away from the current 'one size fits all' approach to T1D treatment. We want to one day be able to offer people treatments tailored to their genes, environment and lifestyle.    Research Holds the Key to that future, but as Professor Barry says, that requires more funding – and we need to act now.